{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma+of+Prostate&page=2", "query": { "condition": "Neuroendocrine Carcinoma of Prostate", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma+of+Prostate&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T02:06:41.647Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05268666", "title": "A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "JBI-802", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jubilant Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2022-04-08", "completion_date": "2025-08", "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 4, "location_summary": "Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05268666" }, { "nct_id": "NCT02893917", "title": "Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 90, "start_date": "2017-08-11", "completion_date": "2027-05-31", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 16, "location_summary": "La Jolla, California • Sacramento, California • San Diego, California + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893917" }, { "nct_id": "NCT00861107", "title": "In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "AlloStim-7", "type": "BIOLOGICAL" }, { "name": "percutaneous tumor cryoablation", "type": "PROCEDURE" }, { "name": "AlloStim8 or AlloStim-9", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mirror Biologics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-08", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 1, "location_summary": "Carlsbad, California", "locations": [ { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861107" }, { "nct_id": "NCT05005728", "title": "XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "vudalimab + carboplatin + cabazitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "vudalimab + olaparib", "type": "COMBINATION_PRODUCT" }, { "name": "vudalimab monotherapy", "type": "BIOLOGICAL" }, { "name": "vudalimab + docetaxel", "type": "COMBINATION_PRODUCT" }, { "name": "vudalimab + cabazitaxel or docetaxel", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT", "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 72, "start_date": "2021-10-22", "completion_date": "2025-06-10", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 26, "location_summary": "Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005728" }, { "nct_id": "NCT07488923", "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer (SCLC )", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)", "Gastroenteropancreatic NEC (GEP NEC)", "Neuroendocrine Prostate Cancer (NEPC)" ], "interventions": [ { "name": "ML261", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Moonlight Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2026-06", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 5, "location_summary": "Hackensack, New Jersey • New York, New York • Nashville, Tennessee + 2 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488923" }, { "nct_id": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "TTX-080", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tizona Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2020-07-14", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 41, "location_summary": "Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04485013" }, { "nct_id": "NCT04373564", "title": "Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Motor Function", "Cognitive Function", "Contrast Media" ], "interventions": [ { "name": "Motor Tests", "type": "PROCEDURE" }, { "name": "Cognitive Tests", "type": "PROCEDURE" }, { "name": "Unenhanced-MRI of the brain", "type": "PROCEDURE" }, { "name": "Gadolinium Measurements", "type": "PROCEDURE" }, { "name": "Gadoxetate disodium", "type": "DRUG" }, { "name": "Gadobenate dimeglumine", "type": "DRUG" }, { "name": "Gadodiamide", "type": "DRUG" }, { "name": "Gadoterate meglumine", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 2076, "start_date": "2021-03-24", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04373564" }, { "nct_id": "NCT03582475", "title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Small Cell Neuroendocrine Carcinoma", "Castration-Resistant Prostate Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Prostate Neuroendocrine Neoplasm", "Prostate Small Cell Carcinoma", "Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8", "Stage III Prostate Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Ureter Small Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-01-11", "completion_date": "2026-12-01", "has_results": true, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03582475" }, { "nct_id": "NCT05819827", "title": "Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer", "Prostate Cancer", "Testicular Cancer", "Bladder Carcinoma", "Genitourinary System Carcinoma", "Malignant Testicular Neoplasm", "Melanoma", "Prostate Carcinoma", "Sarcoma" ], "interventions": [ { "name": "Blood and Tissue", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 13, "start_date": "2023-04-19", "completion_date": "2024-05-21", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05819827" }, { "nct_id": "NCT07118176", "title": "Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Colorectal Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Lung Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Neoplasm of Unknown Primary", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Uterine Neoplasm", "Neuroendocrine Neoplasm", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Penile Carcinoma", "Pleural Carcinomatosis", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Salivary Gland Carcinoma", "Sarcoma", "Skin Carcinoma", "Solitary Fibrous Tumor", "Thymus Carcinoma", "Thyroid Gland Carcinoma", "Thyroid Gland Medullary Carcinoma", "Urothelial Carcinoma", "Vaginal Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gallium Ga 68 FAPi-46", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-01", "completion_date": "2027-09-07", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-06-27T02:06:41.647Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07118176" } ] }